Journal de l'obésité et de la thérapeutique

Obesity Summit 2018: PCSK9 inhibitors: FOURIER study- Govind Kulkarni- Pulse Diabetes, Obesity & Cardiac Relief Center, India

Govind Kulkarni

Background: Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers Low-Density Lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. Methods: We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy. Patients were randomly assigned to receive Evolocumab (either 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina or coronary revascularization. The key secondary efficacy end point was the composite of cardiovascular death, myocardial infarction or stroke. The median duration of follow-up was 2.2 years. Results: At 48 weeks, the least-squares mean percentage reduction in LDL cholesterol levels with Evolocumab, as compared with placebo, was 59%, from a median baseline value of 92 mg per deciliter (2.4 mmol per liter) to 30 mg per deciliter (0.78 mmol per liter) (P